TAPI EHS activities

Keeping the environment in mind!

By Pascal Michoux, Vice-President Global EHS of TAPI & Biologics



A new plan for TAPI to contribute to the reduction of CO2 emissions by 15% by 2020, compared to our 2012 baseline in TEVA.

TAPI is planning to achieve energy efficiencies through investment in engineering improvements, energy management systems, adopting new technologies, and applying “Energy by Design” principles to seek energy savings in every project.

Article North America South America Middle East LATAM South East Asia

We continue to consider opportunities to source renewable energy and establish cogeneration or green energy production where possible. As part of these improvements, we are initiating a plan to minimize refrigerants gas leak and eliminate R-22 refrigerant in our equipment.


Reducing emissions: In our Opava factory in the Czech Republic, we made a change that saves more than 3,000 metric tons of greenhouse gas emissions per year. In 2014, we installed a condensing economizer to increase the efficiency and utilization of natural gas, the basic source of energy for the central steam boiler room at the site. Utilizing the condensing heat of water, which is produced during the combustion of natural gas, significantly increases the efficiency of the boilers and reduces our natural gas consumption.


Reducing waste: In our Villanterio site in Italy, we manufacture the active pharmaceutical ingredient allopurinol that is used to prevent the buildup of uric acid in the body to prevent liver or kidney diseases.

The allopurinol process yields different types of waste. Following detailed analysis of the waste streams, we improved the process by segregating process elements, increasing recovery of solvents and installing new equipment. As a result, we increased the yield of active ingredient by 2.4% and reduced the total unrecovered waste generated through this process.


Pascal Michoux is Vice-President Global EHS of TAPI & Biologics. He is based in Assago (Italy) and has 30 years of experience in the API pharmaceutical industry, in different roles and companies.

For more information about TAPI’s EHS topics, please contact us.